Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02143154 · ClinicalTrials.gov registry record

Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis

A clinical trial of GBS Positive and Women in Labor Given Vancomycin for Prophylaxis, sponsored by Women and Infants Hospital of Rhode Island.

Completed
Registry status
77
Enrollment target
1
Study location

NCT02143154 is a study of GBS Positive and Women in Labor Given Vancomycin for Prophylaxis that has completed, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 77 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02143154, a study of GBS Positive and Women in Labor Given Vancomycin for Prophylaxis, has completed, sponsored by Women and Infants Hospital of Rhode Island.

COMPLETED
Registry status
77 participants
Enrollment target
1
Study location

Study Summary

While it is clear that intrapartum antibiotics reduce neonatal GBS infection rates, the mechanism by which these drugs prevent neonatal GBS is not well established. One postulated theory is antibiotics work to reduce bacterial load in the birth canal; thus decreasing fetal exposure during labor and delivery. To our knowledge, the relationship between vancomycin and vaginal GBS colony counts has never been studied. In this prospective cohort study, our objective is to determine the relationship between intrapartum IV vancomycin and vaginal GBS colony counts.

Study Locations (1)

Rhode Island

  • Women & Infants Hospital - Providence

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2014-10
Est. Completion 2018-10-03

What the Registry Record Tells You About NCT02143154

The ClinicalTrials.gov registry entry for NCT02143154 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with GBS Positive appearing as the primary indexed condition, and to 0 interventions.

NCT02143154 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT02143154 about?

NCT02143154 is a clinical study titled "Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis". While it is clear that intrapartum antibiotics reduce neonatal GBS infection rates, the mechanism by which these drugs prevent neonatal GBS is not well established. One postulated theory is antibiotics work to reduce bacterial load in the birth canal; thus decreasing fetal exposure during labor and ...

What is the current status of trial NCT02143154?

This trial is currently completed. The enrollment target is 77 participants. The study started on 2014-10. Estimated completion is 2018-10-03.

What conditions does trial NCT02143154 study?

This clinical trial studies the following conditions: GBS Positive, Women in Labor Given Vancomycin for Prophylaxis.

Who is sponsoring clinical trial NCT02143154?

This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02143154 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.